Inhaled Alpha-1 Antitrypsin for Pulmonary Exacerbation Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary diseases, particularly in AAT-deficient patients, are inadequate for managing exacerbations, as they do not effectively address the acute imbalance of proteinases and antiproteinases during these episodes, leading to lung damage and frequent hospitalizations, with intravenous augmentation therapy having limitations in availability and efficacy during exacerbations.
Innovation Solution
Administering purified naturally occurring alpha-1 antitrypsin (AAT) via inhalation directly to the lungs during exacerbations, either as a standalone treatment or in addition to intravenous therapy, using a process involving chromatography on ion exchange resins to achieve high purity and stability, allowing for direct delivery to the lung tissue to restore the proteinase/antiproteinase balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravenous augmentation therapy is used to treat AAT-deficient patients, then AAT levels are increased in the blood, but the therapy has limitations in availability and efficacy during exacerbations and does not directly address acute lung tissue damage
Solution Approach 1:
The patent uses inhalation as an intermediary route of administration to deliver AAT directly to the lung tissue, bypassing the bloodstream. This mediator approach allows AAT to reach the site of action (lung parenchyma) more directly and effectively during exacerbations, overcoming the limitations of intravenous therapy where AAT must first circulate through the blood before reaching the lungs.
Solution Approach 2:
The patent transitions from systemic delivery (intravenous) to localized delivery (inhalation to lung tissue). This dimensional change in administration route allows AAT to be delivered directly to the affected tissue, increasing local concentration and efficacy during exacerbations while reducing reliance on blood circulation.
2Ease of operation
If current treatments are used for pulmonary exacerbations, then general symptom management is provided, but the acute imbalance of proteinases and antiproteinases is not effectively addressed, leading to lung damage
Solution Approach 1:
The patent extracts and addresses the specific pathological mechanism (proteinase-antiproteinase imbalance) rather than just treating general symptoms. By delivering AAT directly to the lung tissue during exacerbations, the treatment specifically targets and corrects the underlying biochemical imbalance that causes lung damage, rather than merely managing symptoms.
Solution Approach 2:
The patent applies AAT therapy at the onset of exacerbation to prevent lung damage before it occurs. By administering AAT during the exacerbation episode, the treatment acts preliminarily to counterbalance the surge in proteinase activity, preventing tissue damage rather than treating it after the fact.
3Reliability
If frequent hospitalizations are required for exacerbation management, then patient safety is maintained, but quality of life deteriorates and healthcare resources are consumed
Solution Approach 1:
The patent enables patients to manage exacerbations at home through inhalation therapy, making them self-sufficient rather than requiring hospitalization. Patients can administer AAT themselves during exacerbation episodes, maintaining safety while avoiding the quality of life deterioration and resource consumption associated with frequent hospital visits.
4Manufacturing precision
If high purity AAT is produced through chromatography on ion exchange resins, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs chromatography on ion exchange resins to purify AAT, utilizing changes in ionic parameters to separate and concentrate the protein. This parameter-based purification approach achieves high therapeutic purity while using established biochemical techniques that, although multi-step, are well-characterized and controllable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats exacerbations by delivering therapeutically effective amounts of AAT to the lungs, reducing lung damage, improving pulmonary function, and decreasing the frequency and severity of exacerbations, thereby improving the quality of life for AAT-deficient and non-deficient patients with pulmonary diseases.
Implementation Method 1
a process involving chromatography on ion exchange resins to achieve high purity and stability
Data Source
AI summary
The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha- 1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation.